February 14, 2017
Waldorf Astoria, New York
Panelist: Roger Longman
Real Endpoints LLC
Both innovator companies and payers of medicines have expressed a willingness to look beyond the “fee per pill” model to attributing value to the effects on patients’ health instead. The challenge of reimbursing for curative therapies versus lifelong treatments of chronic conditions presents a special challenge, but one that may shine a light on value- based approaches generally. This session will explore with the innovators making progress on gene therapies how they are envisioning the reimbursement model in ways that all stakeholders might appreciate, including doctors’, patients’, and payers’ perspectives.view event >
May 19, 2020 12:00pm ET
Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman
CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment
May 4, 2020 12:30pm ET
Chief Clinical Officer: Jane F. Barlow, MD, MPH, MBA
Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.
October 16, 2019 - October 18, 2019
New York, NY
Speaker: Jeff Berkowitz
Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs
October 13, 2019 - October 15, 2019
Laguna Beach, CA
Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.
October 2, 2019 1:15pm
San Diego, CA
Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.
May 31, 2019
Waldorf Astoria Chicago Hotel
Speaker: Roger Longman
Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.
Payer & Channel Insights, Marketing Analytics & Business Insights